Margaret Porter Scott

Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor

Robert A Copeland, Nigel J Waters, Lei Jin, 2014, Biopharmaceutics & drug disposition.

Targeting epigenetic enzymes for drug discovery.

Robert A Copeland, E. Olhava, R. Copeland, 2010, Current opinion in chemical biology.

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.

Robert A Copeland, Nigel J Waters, Lei Jin, 2015, Nature chemical biology.

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

Yonghong Xiao, Jen-Chieh Tseng, Robert A Copeland, 2011, Cancer cell.

A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.

D. A. Annis, D Allen Annis, Naim Nazef, 2004, Journal of the American Chemical Society.

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Robert A Copeland, Nigel J Waters, E. Olhava, 2013, Blood.